Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint

  Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with...

Related Keywords

Norway ,Oslo ,Norwegian , ,Oslo University Hospital ,Euronext Oslo Stock Exchange ,Tetanus Epitope Targeting ,Carlos De Sousa ,Chief Executive Officer ,Oslo University ,Ultimovac Tetanus Epitope Targeting ,Abuse Regulation ,Norwegian Securities Trading ,Markets ,